Netherlands: one step closer to less animal testing

27 March 2017

In the future, a part of animal testing for new medicines will no longer be necessary. In most cases, testing on one species of animal instead of two will be sufficient to rule out harmful adverse effects of a medicine during pregnancy, according to official health bodies in the Netherlands.

This is one of the conclusions from studies done by the Dutch Medicines Evaluation Board (MEB) and the National Institute for Public Health and the Environment (RIVM) together with a number of research institutes and educational institutions.

The research results are a great step forward in reducing the use of animal testing during medical research. The results reflect the MEB and RIVM's ambition to create medicine development that is safe for patients without the use of animal testing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK